Visit COVID-19 resources

[Skip to Content]

anti-VEGF

Choice of anti VEGF agents for wet AMD treatments

College Statement Ophthalmologists have a choice of two anti-VEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). Photodynamic therapy is also licensed and approved and still has a role in a small subset of patients.  An anti-VEGF agent is generally used for the treatment of wet AMD

Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly

College Statement This statement refers only to injections of anti –Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly directly through the conjunctiva and sclera using a sharp needle. This statement is the current College position and supersedes older statements on intraocular injections in the ARMD Guidelines for Management (2009) and Maximising Capacity in AMD Services